

# A randomised controlled study of N-Acetylcysteine in liver transplantation

<b>Submission date</b> 12/09/2003	<b>Recruitment status</b> Stopped	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Stopped	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 07/04/2011	<b>Condition category</b> Surgery	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr Christopher Watson

**Contact details**  
Honorary Consultant Surgeon  
University Department of Surgery  
Box 202  
Addenbrooke's Hospital  
Cambridge  
United Kingdom  
CB2 2QQ  
+44 (0)1223 336980  
cjew2@cam.ac.uk

## Additional identifiers

**Protocol serial number**  
N0544103857

## Study information

**Scientific Title**

**Study objectives**

N-Acetylcysteine in liver transplantation

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Not Specified

**Health condition(s) or problem(s) studied**

Surgery: Liver transplant

**Interventions**

Patients undergoing liver transplantation will be randomly allocated to the N-Acetylcysteine group or a control group (no treatment).

Treatment will commence during the liver transplant and continue for 5 days post-operatively. Blood tests and liver biopsies will be taken during the study for analysis.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

N-Acetylcysteine

**Primary outcome(s)**

Not provided at time of registration

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

01/09/2007

**Reason abandoned (if study stopped)**

Lack of staff/facilities/resources

**Eligibility**

**Key inclusion criteria**

Added May 2008:

Adult patients ( $\geq 18$  years) undergoing liver transplant

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

Not Specified

**Key exclusion criteria**

Added May 2008:

Allergy to n-acetyl cysteine

**Date of first enrolment**

06/09/2001

**Date of final enrolment**

01/09/2007

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

Honorary Consultant Surgeon

Cambridge

United Kingdom

CB2 2QQ

**Sponsor information****Organisation**

Department of Health (UK)

## **Funder(s)**

**Funder type**  
Government

**Funder Name**  
Cambridge Consortium - Addenbrooke's (UK)

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration